HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population.

AbstractOBJECTIVES:
Asymmetric dimethylarginine (ADMA) has raised considerable interest, as it is an endogenous inhibitor of nitric oxide synthesis. While increased plasma levels of ADMA have been reported in different cardiovascular disease states, its association with symmetric dimethylarginine (SDMA) has not been evaluated in a prospective population-based study.
METHODS AND RESULTS:
We performed a mass spectrometry-based analysis of ADMA and SDMA in the plasma of 572 participants of the Bruneck study. Levels of ADMA and SDMA were significantly correlated with each other (r=0.189, p<0.001). Age and parameters of renal function, however, showed a stronger influence on SDMA than on ADMA. Both ADMA and SDMA were predictive of cardiovascular disease in multivariate analysis and the associated hazard ratios over the 5-year observation period were of similar strength: 3.86 (1.36-10.9) and 7.91 (1.94-32.3) for ADMA and SDMA, respectively (p=0.011 and 0.004). Separate analyses focused on quintile groups of SDMA revealed that the increase in cardiovascular risk was mainly confined to the top category (>0.80 micromol/L).
CONCLUSION:
This study argues against an exclusive ADMA effect in mediating cardiovascular risk. Instead, SDMA, its supposedly inactive counterpart, has similar diagnostic value in this large prospective cohort.
AuthorsStefan Kiechl, Terry Lee, Peter Santer, Graham Thompson, Sotirios Tsimikas, Georg Egger, David W Holt, Johann Willeit, Qingbo Xu, Manuel Mayr
JournalAtherosclerosis (Atherosclerosis) Vol. 205 Issue 1 Pg. 261-5 (Jul 2009) ISSN: 1879-1484 [Electronic] Ireland
PMID19100547 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Nitric Oxide
  • symmetric dimethylarginine
  • N,N-dimethylarginine
  • Arginine
Topics
  • Adult
  • Aged
  • Arginine (analogs & derivatives, metabolism)
  • Cardiovascular Diseases (blood, diagnosis)
  • Cohort Studies
  • Female
  • Humans
  • Male
  • Mass Spectrometry (methods)
  • Middle Aged
  • Nitric Oxide (metabolism)
  • Proportional Hazards Models
  • Prospective Studies
  • Risk

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: